Covid 19 Research using Clinical Trials (Home Page)
Report for D015212: Inflammatory Bowel Diseases NIH
(Synonyms: Inflammatory Bowe, Inflammatory Bowel, Inflammatory Bowel Di, Inflammatory Bowel Disease, Inflammatory Bowel Diseases)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (6)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug878 | Examine the impact of COVID-19 during pregnancy Wiki | 0.50 |
| drug2578 | Two doses of placebo at the schedule of day 0,28 Wiki | 0.50 |
| drug2572 | Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Wiki | 0.50 |
| drug2571 | Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Wiki | 0.50 |
| drug2575 | Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 Wiki | 0.50 |
| drug1243 | Interview Wiki | 0.29 |
Correlated MeSH Terms (5)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007410 | Intestinal Diseases NIH | 0.50 |
| D003092 | Colitis NIH | 0.20 |
| D003093 | Colitis, Ulcerative NIH | 0.20 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| D018352 | Coronavirus Infections NIH | 0.02 |
Correlated HPO Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002037 | Inflammation of the large intestine HPO | 1.00 |
| HP:0002242 | Abnormal intestine morphology HPO | 0.50 |
| HP:0002583 | Colitis HPO | 0.20 |
| HP:0100279 | Ulcerative colitis HPO | 0.20 |
There are 4 clinical trials
Clinical Trials
1 Prospective Multicenter Cohort of Patients With Inflammatory Bowel Disease Treated by Infliximab or Vedolizumab During COVID-19 Pandemic
Multicenter cohort of patients followed for 6 months during the pandemic in France with biocollection of sera and peripheral blood mononuclear cells
NCT04344249 IBD COVID MeSH:Inflammatory Bowel Diseases
HPO:Inflammation of the large intestine
Primary Outcomes
Description: Impact of antibodies du to immunosuppressive protocol on the risk of viral infection
Measure: IgG and IgM anti SARS-CoV-2 Time: through study completion, an average of 2 year
Secondary Outcomes
Description: Describe clinical factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.
weight (Kg)
height (m)
ABO Group ....
Measure: Clinical factors and severity of COVID-19 infection Time: through study completion, an average of 2 year
Description: Describe demographic factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.
ACCOMMODATION
HOUSING AREA
number of people at home ....
Measure: demographic factors and severity of COVID-19 infection Time: through study completion, an average of 2 year
Description: Describe residual rates of treatments (edolizumab or infliximab) of the population of IBD patients who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.
Measure: pharmacologic factors and severity of COVID-19 infection Time: through study completion, an average of 2 year
2 The Effect of Patient's Perceptions for COVID-19 on the Inflammatory Bowel Disease-related Healthcare Utilization in the Hyperepidemic Area
Primary Outcomes
Description: Impact of antibodies du to immunosuppressive protocol on the risk of viral infection
Measure: IgG and IgM anti SARS-CoV-2 Time: through study completion, an average of 2 yearSecondary Outcomes
Description: Describe clinical factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management. weight (Kg) height (m) ABO Group ....
Measure: Clinical factors and severity of COVID-19 infection Time: through study completion, an average of 2 yearDescription: Describe demographic factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management. ACCOMMODATION HOUSING AREA number of people at home ....
Measure: demographic factors and severity of COVID-19 infection Time: through study completion, an average of 2 yearDescription: Describe residual rates of treatments (edolizumab or infliximab) of the population of IBD patients who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.
Measure: pharmacologic factors and severity of COVID-19 infection Time: through study completion, an average of 2 yearThe rapid spread of COVID-19 is expected to have a significant impact on medicine as well as all sectors worldwide. In particular, inflammatory bowel disease (IBD) is a chronic immune disease in which remission and activation are repeated and must be treated consistently throughout life. In addition, patients with IBD may be vulnerable to various infectious diseases due to the immuno-compromised state due to the use of immuno-suppressants or biological agents. During a pandemic, patients with IBD may postpone hospital visits due to concerns about infection with COVID-19, and if they cannot continue drug treatment, there is a concern about the flare up IBD disease activity. Therefore, in this study, we would like to investigate the current status of hospital utilization of IBD patients in Daegu, the epidemic area of COVID-19, and to investigate the effect of patient perception of COVID-19 on hospital ultilization.
NCT04387279 COVID-19 Perception, Self Facilities and Services Utilization Other: Interview MeSH:Inflammatory Bowel Diseases
HPO:Inflammation of the large intestine
Primary Outcomes
Description: Correlation between patient's perception of COVID-19 and medical use patterns during the pandemic period
Measure: Patient's perception of COVID-19 and medical use patterns Time: 1day
Secondary Outcomes
Description: Exacerbation of symptoms in patients with IBD during the pandemic period
Measure: Exacerbation of symptoms Time: 1day
3 PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic
Primary Outcomes
Description: Correlation between patient's perception of COVID-19 and medical use patterns during the pandemic period
Measure: Patient's perception of COVID-19 and medical use patterns Time: 1daySecondary Outcomes
Description: Exacerbation of symptoms in patients with IBD during the pandemic period
Measure: Exacerbation of symptoms Time: 1dayTo find out what adaptations have been made by Inflammatory bowel disease physicians and patients in relation to therapies in flaring IBD patients during severe acute respiratory syndrome 2-COV and what the impact of these is on IBD patients with no symptomatic COVID-19 and in suspected/confirmed COVID-19. Also whether there any IBD related factors impacting the outcome of patients with COVID-19 symptoms or COVID-19 disease
NCT04410484 Inflammatory Bowel Diseases Coronavirus Infection MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Intestinal Diseases Inflammatory Bowel Diseases
HPO:Abnormal intestine morphology Inflammation of the large intestine
Primary Outcomes
Measure: Flare of IBD needing change in therapy or surgery Time: 3 months
4 PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis: A Multi-centre Observational Case- Control Study
Primary Outcomes
Measure: Flare of IBD needing change in therapy or surgery Time: 3 monthsWhether the perceived changes in management of Acute Severe Ulcerative Colitis during the COVID pandemic are widespread, and whether they have any impact on patient outcomes
NCT04411784 Inflammatory Bowel Diseases COVID MeSH:Colitis Colitis, Ulcerative Inflammatory Bowel Diseases
HPO:Colitis Inflammation of the large intestine Ulcerative colitis
Primary Outcomes
Description: The need for in-hospital colectomy or rescue therapy
Measure: Primary outcome measure: The need for in-hospital colectomy or rescue therapy Time: 3 months
Secondary Outcomes
Description: Duration and type/route of steroid use
Measure: 2.1: Duration and type/route of steroid use Time: 3 months
Description: 30 day colectomy free survival rates
Measure: 2.2: 30 day colectomy free survival rates Time: 3 months
Description: Covid-19 infection rates
Measure: 2.3: Covid-19 infection rates Time: 3 months
Description: Rate of Rescue therapy use
Measure: 2.4: Rate of Rescue therapy use Time: 3 months
Description: Duration of hospital stay
Measure: 2.5: Duration of hospital stay Time: 3 months
Description: Admission severity scoring
Measure: 2.6: Admission severity scoring Time: 3 months
Description: Readmission rates
Measure: 2.7: Readmission rates Time: 3 months
HPO Nodes
HP:0002037: Inflammation of the large intestine
Genes 57
RFXANK MAP3K7 NLRC4 IL10RA WIPF1 BACH2 STAT1 FOXP3 RTEL1 FASLG ABCB1 WAS NOD2 TGFB1 IL10RB CASP10 XIAP FAS MASP2 RIPK1 IRGM ZAP70 COG6 RASGRP1 FERMT1 CIITA INAVA OPLAH GPR35 MST1 HLA-DRB1 CARMIL2 WAS TTC37 SKIV2L SLC9A3 PLCG2 ARPC1B SKIV2L LRBA RFX5 HLA-B TNFAIP3 FAS IL6 ZAP70 RFXAP NCF4 F13A1 PRKCD TCF4 RET POLA1 F13B IL21 HPS1 GPIHBP1 Protein Mutations 1
R139C
Primary Outcomes
Description: The need for in-hospital colectomy or rescue therapy
Measure: Primary outcome measure: The need for in-hospital colectomy or rescue therapy Time: 3 monthsSecondary Outcomes
Description: Duration and type/route of steroid use
Measure: 2.1: Duration and type/route of steroid use Time: 3 monthsDescription: 30 day colectomy free survival rates
Measure: 2.2: 30 day colectomy free survival rates Time: 3 monthsDescription: Covid-19 infection rates
Measure: 2.3: Covid-19 infection rates Time: 3 monthsDescription: Rate of Rescue therapy use
Measure: 2.4: Rate of Rescue therapy use Time: 3 monthsDescription: Duration of hospital stay
Measure: 2.5: Duration of hospital stay Time: 3 monthsDescription: Admission severity scoring
Measure: 2.6: Admission severity scoring Time: 3 monthsDescription: Readmission rates
Measure: 2.7: Readmission rates Time: 3 months